POPULATION PHARMACOKINETICS OF BRENTUXIMAB VEDOTIN, AN ANTIBODY-DRUG CONJUGATE (ADC), IN PATIENTS WITH CD30-POSITIVE HEMATOLOGIC MALIGNANCIES.

被引：0
|
作者：
Li, H. [1 ]
Han, T. H. [2 ]
Hunder, N. [1 ]
Jang, G. [1 ]
Zhao, B. [1 ]
机构：
[1] Seattle Genet, Bothell, WA USA
[2] Stemcentrx Inc, San Francisco, CA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-041
引用
收藏
页码：S41 / S42
页数：2
相关论文
共 50 条
  • [11] PERIPHERAL NEUROTOXICITY IN PATIENTS WITH CD30-POSITIVE MALIGNANCIES, TREATED WITH BRENTUXIMAB VEDOTIN
    Plasmati, R.
    Pastorelli, F.
    Salvi, F.
    Zinzani, P. L.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2013, 18 : 26 - 27
  • [12] BRENTUXIMAB VEDOTIN Anti-CD30 Antibody-Drug Conjugate Oncolytic
    Copeland, A.
    Younes, A.
    DRUGS OF THE FUTURE, 2010, 35 (10) : 797 - 801
  • [13] Retreatment with brentuximab vedotin in CD30-positive hematologic malignancies: A phase II study.
    Bartlett, Nancy
    Brice, Pauline
    Chen, Robert W.
    Fanale, Michelle A.
    Gopal, Ajay K.
    Matous, Jeffrey
    Rosenblatt, Joseph David
    Grove, Laurie E.
    Forero-Torres, Andres
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [14] CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin
    Lobastova, Liudmila
    Lettau, Marcus
    Babatz, Felix
    de Oliveira, Thais Dolzany
    Nguyen, Phuong-Hien
    Pauletti, Bianca Alves
    Schauss, Astrid C.
    Duerkop, Horst
    Janssen, Ottmar
    Paes Leme, Adriana F.
    Hallek, Michael
    Hansen, Hinrich P.
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [15] PERIPHERAL NEUROTOXICITY IN PATIENTS WITH CD30-POSITIVE MALIGNANCIES, TREATED WITH BRENTUXIMAB VEDOTIN
    Plasmati, R.
    Pastorelli, F.
    Salvi, F.
    Zinzani, P. L.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2012, 17 : S46 - S46
  • [16] Clinical Binding Properties, Internalization Kinetics, and Clinicopathologic Activity of Brentuximab Vedotin: An Antibody-Drug Conjugate for CD30-Positive Lymphoid Neoplasms
    Fromm, Jonathan R.
    McEarchern, Julie A.
    Kennedy, Dana
    Thomas, Anju
    Shustov, Andrei R.
    Gopal, Ajay K.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (04): : 280 - 283
  • [17] Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies
    Han, T. H.
    Chen, R.
    Advani, R.
    Berryman, R. B.
    Smith, S. E.
    Forero-Torres, A.
    Rosenblatt, J. D.
    Smith, M. R.
    Zain, J.
    Hunder, N. N.
    Engert, A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (01) : 241 - 249
  • [18] A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
    Fanale, Michelle A.
    Forero-Torres, Andres
    Rosenblatt, Joseph D.
    Advani, Ranjana H.
    Franklin, Anna R.
    Kennedy, Dana A.
    Han, Tae H.
    Sievers, Eric L.
    Bartlett, Nancy L.
    CLINICAL CANCER RESEARCH, 2012, 18 (01) : 248 - 255
  • [19] Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies
    T. H. Han
    R. Chen
    R. Advani
    R. B. Berryman
    S. E. Smith
    A. Forero-Torres
    J. D. Rosenblatt
    M. R. Smith
    J. Zain
    N. N. Hunder
    A. Engert
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 241 - 249
  • [20] Brentuximab vedotin for CD30-positive tumours
    Masuda, Shigeo
    Miyagawa, Shigeru
    Nakamura, Terumi
    Khurram, Maaz Asher
    Sawa, Yoshiki
    LANCET ONCOLOGY, 2016, 17 (09): : E371 - E371
12345